Pfizer Inc. (NYSE:PFE) Leerink Partners Global Biopharma Conference 2024 Call March 12, 2024 8:00 AM ET Company Participants Ronen Tamir - Vice President, Investor Relations Mikael Dolsten - Chief Scientific Officer & President, Pfizer Research and Development Conference Call Participants David Risinger - Leerink Partners David Risinger Good morning, everybody. So it's very much my pleasure to start off the day today with Pfizer's Head of R&D, Mikael Dolsten. It's very much my pleasure to welcome him. And R ...

ToplinePfizer’s cancer drug Adcetris extended survival in patients with a common form of lymphoma in a late-stage trial, the company announced Tuesday, supporting Pfizer’s efforts to expand into cancer treatments amid declining Covid vaccine sales.The drugmaker invested in cancer drugs last year amid declining Covid vaccine sales. Getty Images Key FactsPatients with diffuse large B-cell lymphoma showed a “statistically significant and clinically meaningful improvement” in overall survival—the amount of time ...

Michael M. SantiagoIntroduction On December 21, 2023, I wrote about Pfizer Inc. (NYSE:PFE) stock for the first time after a long hiatus since initiating coverage in November 2021. Last time, I wrote about PFE appearing oversold and undervalued due to likely underestimated EPS forecasts for FY 2025 and beyond. I urged not to panic, but to think about building a long position at the low price levels. Unfortunately, the PFE stock has since significantly underperformed the broader market: Seeking Alpha, my ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study of the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo. Positive outcomes were also observed in key secondary endpoints, inclu ...

Pfizer is pushing to be more involved in cancer drugs after a turbulent year marked by the rapid decline of its COVID business.During a four-hour investor event last week, Pfizer pushed its initative to “accelerate breakthroughs that help people with cancer globally live better and longer lives,” according to CNBC.The drugmaker has ramped up its efforts to “outdo cancer” since it acquired oncology biotech firm Seagen for $43 billion in December.The acquisition doubled Pfizer’s cancer drug pipeline to 60 dif ...

Dividend stocks are great for several reasons. Some use the regular payouts they offer to complement their income, whether in retirement or otherwise, while others reinvest the money to boost long-term returns. Dividend stocks have generally outperformed their non-dividend-paying peers over long periods.Clearly, this mode of investing has advantages, but if there's one thing better than investing in dividend stocks, it's investing in cheap dividend stocks. Let's consider two companies that fit the bill: Pfi ...

Sometimes quality companies that have fallen on hard times can make for great investments. The market usually sells off their stocks to levels more than warranted when the underlying business hits a lean patch, or fails to meet the market's baked-in expectations, over the short term. But if the long-term prospects are fundamentally intact, such market actions merely make the stocks cheap, making them ripe pickings for value investors. However, it's also true that many investors have lost their shirts by bet ...

Nurphoto | Nurphoto | Getty ImagesPfizer is ready to move on from Covid. Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. It just might take a while before that bet pays off. Pfizer pitched its deeper push into oncology during a four-hour investor event last week. And it had a splashy 60-second Super Bowl ad that touted its initiative to "outdo cancer." The shift comes at a crucial time for Pfizer. The pharmaceuti ...

JHVEPhotoPfizer's (NYSE:PFE) stock has cratered following the end of its freefall profits from COVID-related vaccine sales. In fact, Pfizer's stock is down by nearly 55% from its ATH in late 2021 and roughly 50% below its high in late 2022. Pfizer's market cap melted from over $330 billion to around $150 billion, approximately a 13-year low. Market cap (companiesmarketcap.com )However, despite Pfizer's post-COVID-19 melt-up and subsequent meltdown, it remains a solid market-leading company with consider ...

Per Cantor Fitzgerald analyst Louise Chen's calculations published March 4, Pfizer's (PFE 4.26%) stock is going to climb by around 75% to reach or surpass $45 over the coming quarters. Chen's hypothesis for the biopharma is likely linked to its ongoing pivot away from its coronavirus medicines like Paxlovid and Comirnaty, and toward the revenue sources of the future, which management has designated as cancer therapeutics.But is Pfizer a buy today, with a price tag around $26, and with its new oncology pipel ...